

IN THE SPECIFICATION

On page 11, please replace the paragraph at lines 5 to 7 with the following replacement paragraph:

5 A trans-dermal skin patch using my combinations can achieve the same benefit of minimizing ~~the risk of unwanted pregnancy~~premenstrual symptoms. For example, one can prepare a trans-dermal hormone replacement therapy daily skin patch as follows:

A clean copy of the replacement paragraph therefore reads as follows:

10 A trans-dermal skin patch using my combinations can achieve the same benefit of minimizing premenstrual symptoms. For example, one can prepare a trans-dermal hormone replacement therapy daily skin patch as follows:

On page 11, please replace the paragraph at lines 15 to 22 with the following replacement paragraph:

With respect to the dosage amount of the pharmaceutical components used here, the specific dose may vary depending on the age and weight of the patient, the severity of the symptoms, the incidence of ~~non-teratogenic~~ side effects ~~and the like.~~ For ~~isotretinoin~~, for example, it is known in the art to administer 5-40 milligrams of ~~isotretinoin~~ two times per day. Similarly, for a contraceptive, it is known in the art to use estrogen, 20 or more micrograms per day, or gestodene 75 micrograms per day together with 20-30 micrograms per day of ethinyl estradiol per day. Other currently-known contraceptive preparations are discussed in my Information Disclosure Statement Petition To Make Special at Shangold *et al.*, United States Letters Patent No. 6,214,815.

A clean copy of the paragraph reads as follows:

With respect to the dosage amount of the pharmaceutical components used here, the specific dose may vary depending on the age and weight of the patient, the severity of the symptoms, the incidence of side effects . For example, for a contraceptive, it is known in the art to use estrogen, 20 or more micrograms per day, or gestodene 75 micrograms per day together with 20-30 micrograms per day of ethinyl estradiol per day. Other currently-known contraceptive preparations are discussed in my Petition To Make Special at Shangold *et al.*, United States Letters Patent No. 6,214,815.

*Premenstrual Dysphoric Disorder Medication*

By Matthew D. IAMMATTEO, M.D.

Filed 6 May 04

On page 12, please replace the paragraph at lines 6 to 9 with the following replacement paragraph:

With respect to hormone replacement therapy, I propose to lower and lessen the doses of the SSRI in same distribution as mentioned above with estrogen alone (0.3 to 1.25 gmg per day) , for women who have a uterus, or, for women lacking ovaries-a uterus (e.g., post-hysterectomy women), estrogen (0.3 to 1.25 mg per day) combined with progesterone (1.5 to 10 mg per day).

A clean copy of the replacement paragraph therefore reads as follows:

With respect to hormone replacement therapy, I propose to lower and lessen the doses of the SSRI in same distribution as mentioned above with estrogen alone (0.3 to 1.25 mg per day) , for women who have a uterus, or, for women lacking a uterus (e.g., post-hysterectomy women), estrogen (0.3 to 1.25 mg per day) combined with progesterone (1.5 to 10 mg per day).

15